Chapter X Drug Study

NAME OF DRUG THERAPEUTIC ACTION GENERIC Adrenergic NAME: bronchodilators and Ansimar phosphodiesterase inhibitors both work by increasing intracellular level of cyclic-3,5- adenosine monophosphate BRAND NAME: (cAMP); adrenergics Doxofylline by increasing production and phosphodiesterase CLASSIFICATIO inhibitorsby decreasing breakdown. N: Antiasthmatic & Increased levels of cAMP produce COPD bronchodilation.Cortic Preparations osteroids act by decreasing airway inflammation. Anticholinergics(ipratr opium) produce brondhodilation by decreasing intracellular levels ofcyclic guanosine monophosphate (cGMP). Leukotriene receptor antagonists INDICATIONS Bronchial asthma & pulmonary disease w/ spastic bronchial component. CONTRA INDICATIONS Acute MI, hypotension, lactation ADVERSE EFFECT Nausea, vomiting, epigastric pain, cephalalgia, irritability, insomnia, tachycardia, extrasystole, tachypnea, hyperglycemia, albuminuria. NURSING CONSIDERATION >Assess lung sounds, pulse and blood pressure before administration and during peak of medication. Not amount, color, and character of sputum produced. > Monitor pulmonary function tests before initiating therapy and periodically during therapy to determine effectiveness of medication.

andmast cell stabilizers decrease the release of substances that can contribute tobronchospasm.

>

Observe for

paradoxical bronchospasm (wheezing). If conditions occur, withhold medication and notify physician of other health care professional immediately